Results of a world-first phase 3 trial for secondary progressive multiple sclerosis (MS), led by UCL researchers, have shown ...

Confirmed six-month disability progression rates over 4 years were similar in patients given the oral statin or a placebo in ...

PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE DEVELOPMENT OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE ...

Analyst Eric Le Berrigaud from Stifel Nicolaus maintained a Buy rating on Sanofi (SNYNF – Research Report) and increased the price target ...

The revisions signal a shift toward looking at MS more as a biologically based disease, noted Xavier Montalban, MD, PhD, of ...

Thirty-one Mississippi State students are new scholarship recipients in one of the state’s most prestigious teacher education ...

Candidates participating in this year’s general election were invited to submit information to the League of Women Voters of ...

Osteopenia was originally a qualitative term denoting bone that appeared to be less dense on radiographs. Since 1994, it has ...